Factsheet data is now cached locally - if you have visited a page you can now view it offline!
Are you a harm reduction organisation using TripSit? Let us know about you!
1B-LSD (1-butanoyl-lysergic acid diethylamide) is an LSD analogue which appears to be about as potent as 1P-LSD (slightly more potent than LSD) and has a slightly shorter duration than that of LSD, again thought to be about the same as 1P-LSD. Released in late 2018, and marketed agressively as a replacement for 1P-LSD. 1B-LSD does not yet have a clearly established safety profile,
Drugs marked as tentative are those our team wasn't able to find much reliable information about. This is often because the drug is very new. Information listed under these drugs should not be entirely trusted.
Research chemicals are drugs with relatively little history of human use, and thus particular care should be taken if choosing to ingest them.Read more on TripSit Wiki...
NOTE: At the time of this chemical's release, the manufacturers claimed 1B-LSD was expected to be slightly less potent than 1P-LSD, supposedly owing to the increased mass of the butanoyl group over the propionyl group, however anecdotes seem to indicate approximate equipotency to 1P-LSD.
No interaction information for 1B-LSD